This new bioassay represents a major breakthrough in assessing the potency of lentiviral vectors for CAR-T therapies. Unlike traditional methods that may overestimate functional titer, this assay specifically targets only fully functional viral particles, making it an excellent tool for quality control of lentiviral vectors in production.